Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific: Increase of equity position in paclitaxel supplier Natural Pharmaceuticals, Inc. through the acquisition of additional shares builds on exclusive August 2001 supply agreement, Boston Scientific says (1"The Gray Sheet" August 20, 2001, p. 9). Privately held NPI, which has a proprietary technology for extracting paclitaxel from yew trees, has granted Boston Scientific a "long-term" extension. "We are very pleased to be extending our relationship with NPI, particularly in light of the growing body of evidence that paclitaxel appears to be a safe and effective treatment for coronary artery disease," Boston Scientific Chief Technology Officer Fred Colen comments July 9. Specific terms of the deal are not being disclosed...